248 related articles for article (PubMed ID: 23735593)
1. Safety of cycloserine and terizidone for the treatment of drug-resistant tuberculosis: a meta-analysis.
Hwang TJ; Wares DF; Jafarov A; Jakubowiak W; Nunn P; Keshavjee S
Int J Tuberc Lung Dis; 2013 Oct; 17(10):1257-66. PubMed ID: 23735593
[TBL] [Abstract][Full Text] [Related]
2. Serious treatment related adverse drug reactions amongst anti-retroviral naïve MDR-TB patients.
Van der Walt M; Lancaster J; Odendaal R; Davis JG; Shean K; Farley J
PLoS One; 2013; 8(4):e58817. PubMed ID: 23573193
[TBL] [Abstract][Full Text] [Related]
3. [Rezonizat and cycloserine in complex therapy of drug resistant tuberculosis (comparative studies)].
Sokolova GB; Lazareva IaR; Kirtaeva OV; Romanova EV; Tsybane AA
Antibiot Khimioter; 2008; 53(11-12):25-8. PubMed ID: 19441654
[TBL] [Abstract][Full Text] [Related]
4. Steady state pharmacokinetics of cycloserine in patients on terizidone for multidrug-resistant tuberculosis.
Court R; Wiesner L; Stewart A; de Vries N; Harding J; Maartens G; Gumbo T; McIlleron H
Int J Tuberc Lung Dis; 2018 Jan; 22(1):30-33. PubMed ID: 29297422
[TBL] [Abstract][Full Text] [Related]
5. Neuropsychiatric toxicity and cycloserine concentrations during treatment for multidrug-resistant tuberculosis.
Court R; Centner CM; Chirehwa M; Wiesner L; Denti P; de Vries N; Harding J; Gumbo T; Maartens G; McIlleron H
Int J Infect Dis; 2021 Apr; 105():688-694. PubMed ID: 33684562
[TBL] [Abstract][Full Text] [Related]
6. Treatment Outcomes and Adverse Drug Effects of Ethambutol, Cycloserine, and Terizidone for the Treatment of Multidrug-Resistant Tuberculosis in South Africa.
van der Walt ML; Shean K; Becker P; Keddy KH; Lancaster J
Antimicrob Agents Chemother; 2020 Dec; 65(1):. PubMed ID: 33046491
[TBL] [Abstract][Full Text] [Related]
7. Steady-state population pharmacokinetics of terizidone and its metabolite cycloserine in patients with drug-resistant tuberculosis.
Mulubwa M; Mugabo P
Br J Clin Pharmacol; 2019 Sep; 85(9):1946-1956. PubMed ID: 31046167
[TBL] [Abstract][Full Text] [Related]
8. [A case of multi-drug resistant tuberculosis showing psychiatric adverse effect by cycloserine].
Fujita J; Sunada K; Hayashi H; Hayashihara K; Saito T
Kekkaku; 2008 Jan; 83(1):21-5. PubMed ID: 18283911
[TBL] [Abstract][Full Text] [Related]
9. Psychiatric issues in the management of patients with multidrug-resistant tuberculosis.
Vega P; Sweetland A; Acha J; Castillo H; Guerra D; Smith Fawzi MC; Shin S
Int J Tuberc Lung Dis; 2004 Jun; 8(6):749-59. PubMed ID: 15182146
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and safety of World Health Organization group 5 drugs for multidrug-resistant tuberculosis treatment.
Winters N; Butler-Laporte G; Menzies D
Eur Respir J; 2015 Nov; 46(5):1461-70. PubMed ID: 26381514
[TBL] [Abstract][Full Text] [Related]
11. Cycloserine-induced Stevens-Johnson syndrome in an AIDS patient with multidrug-resistant tuberculosis.
Akula SK; Aruna AS; Johnson JE; Anderson DS
Int J Tuberc Lung Dis; 1997 Apr; 1(2):187-90. PubMed ID: 9441086
[TBL] [Abstract][Full Text] [Related]
12. Population Pharmacokinetics of Cycloserine and Pharmacokinetic/Pharmacodynamic Target Attainment in Multidrug-Resistant Tuberculosis Patients Dosed with Terizidone.
Chirehwa MT; Court R; de Kock M; Wiesner L; de Vries N; Harding J; Gumbo T; Maartens G; Warren R; Denti P; McIlleron H
Antimicrob Agents Chemother; 2020 Oct; 64(11):. PubMed ID: 32816738
[TBL] [Abstract][Full Text] [Related]
13. Linezolid for the treatment of complicated drug-resistant tuberculosis: a systematic review and meta-analysis.
Cox H; Ford N
Int J Tuberc Lung Dis; 2012 Apr; 16(4):447-54. PubMed ID: 22325685
[TBL] [Abstract][Full Text] [Related]
14. Cycloserine-induced psychosis in a young female with drug-resistant tuberculosis.
Sharma B; Handa R; Nagpal K; Prakash S; Gupta PK; Agrawal R
Gen Hosp Psychiatry; 2014; 36(4):451.e3-4. PubMed ID: 24766906
[TBL] [Abstract][Full Text] [Related]
15. [Russian cycloserine in complex therapy of drug resistant tuberculosis].
Sokolova GB; Kirtaeva OV; Lazareva IaV; Tsybanev AA
Antibiot Khimioter; 2008; 53(5-6):32-4. PubMed ID: 19069180
[No Abstract] [Full Text] [Related]
16. Prevalence and incidence of symmetrical symptomatic peripheral neuropathy in patients with multidrug-resistant TB.
Conradie F; Mabiletsa T; Sefoka M; Mabaso S; Louw R; Evans D; Van Rie A
S Afr Med J; 2013 Oct; 104(1):24-6. PubMed ID: 24388081
[TBL] [Abstract][Full Text] [Related]
17. Neuropsychiatric reactions induced by cycloserine in the treatment of multidrug-resistant tuberculosis: what an Indian female patient tells us.
Intini E; Kishore G; Richeldi L; Udwadia ZF
BMJ Case Rep; 2019 Dec; 12(12):. PubMed ID: 31806629
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and safety of cycloserine-containing regimens in the treatment of multidrug-resistant tuberculosis: a nationwide retrospective cohort study in China.
Wang J; Pang Y; Jing W; Chen W; Guo R; Han X; Wu L; Yang G; Yang K; Chen C; Jiang L; Cai C; Dou Z; Diao L; Pan H; Wang J; Du F; Xu T; Wang L; Li R; Chu N
Infect Drug Resist; 2019; 12():763-770. PubMed ID: 31040707
[TBL] [Abstract][Full Text] [Related]
19. Group 5 drugs for multidrug-resistant tuberculosis: individual patient data meta-analysis.
Fox GJ; Benedetti A; Cox H; Koh WJ; Viiklepp P; Ahuja S; Pasvol G; Menzies D;
Eur Respir J; 2017 Jan; 49(1):. PubMed ID: 28049171
[TBL] [Abstract][Full Text] [Related]
20. Amount of Cycloserine Emanating from Terizidone Metabolism and Relationship with Hepatic Function in Patients with Drug-Resistant Tuberculosis.
Mulubwa M; Mugabo P
Drugs R D; 2019 Sep; 19(3):289-296. PubMed ID: 31396892
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
